As I’ve said many times, Cancer is one of the most, if not the most, promising and blockbuster indications for leronlimab. According to NP, the CTC of all the mTNBC patients has gone to zero. If CTCs in all the mTNBC patients in the official trial goes to zero or at least below 5 after starting leronlimab, this will be a breakthrough in medical history. Stopping CTCs may strongly reduce the metastasis of the primary tumor or stop it all together. This is in addition to leronlimab potentially shrinking the primary and metastatic tumor(s).

What I would like to know is why hasn’t CYDY expanded the number of sites at which cancer trials are enrolling? Right now they’re only enrolling in San Francisco and Chicago, according to clinicaltrials.gov. Back in Feb/Mar, NP mentioned a meeting of oncologist, hosted by CYDY, go discuss the drug and the path forward. I don’t think that meeting happened because of COVId, but CYDY could still host a virtual event to get the word out and increase sites and recruiting.